CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors

CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors

SAN FRANCISCO, Mar 06, 2012 (BUSINESS WIRE) -- CytomX Therapeutics, Inc., a leader in the field of highly targeted monoclonal antibody therapies, today announced the appointment of Hoyoung Huh, M.D., Ph.D., as chairman of the Board of Directors. Former chairman Charles Homcy, M.D., venture partner at Third Rock Ventures, will continue to serve on the Board of Directors.

"We are very pleased that Hoyoung will be joining us at such a pivotal point in CytomX's growth and evolution," said Sean McCarthy, D. Phil., chief executive officer of CytomX. "His extensive experience leading biotech companies and his proven expertise in forging strategic corporate relationships are an invaluable addition. I look forward to working closely with Hoyoung, Charles and our full board to advance our strategic agenda as we develop a pipeline of innovative Probody(TM) therapeutics and move our first candidates into development."

Dr. Huh currently serves as chairman of the Geron Corporation, where he has also held executive chairman and director positions, and on the Board of Directors for Addex Pharmaceuticals and BayBio. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the U.S., Europe and Asia. He was previously president, CEO and chairman of BiPar Sciences, Inc., which was acquired by Sanofi-aventis for $500 million in 2009. Dr. Huh also served as chairman of Epizyme, Inc. and has held board positions with Facet Biotech and Nektar Therapeutics, where he was the chief operating officer. Previously, Dr. Huh was a partner at McKinsey & Company. Dr. Huh holds a B.S. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. from Cornell University/ Sloan-Kettering Institute.

"CytomX's highly differentiated platform brings a transformational approach to biologics targeting," said Dr. Huh. "I am delighted to join as chairman of the board and work closely with this visionary leadership team to realize the full potential of the Probody(TM) platform."

About CytomX Therapeutics

CytomX Therapeutics, Inc. is a privately funded biotechnology company developing the Probody(TM) Platform. Probodies are a unique class of fully recombinant, protease-activated monoclonal antibodies designed to leverage protease dysregulation within disease microenvironments, a hallmark of many pathologies, to achieve unprecedented levels of tissue-specific targeting. Probodies expand the therapeutic index for targets with validated disease biology but with normal tissue expression patterns that are too widespread to allow for adequate safety margins using conventional antibody approaches. This highly innovative platform is broadly enabling to all common antibody formats including bispecifics, multispecifics and antibody-drug conjugates. Our mission is to build value through the creation of a pipeline of Probody(TM) therapeutics with an initial focus in oncology, inflammatory disease and autoimmune conditions. Our lead programs are directed against a portfolio of promising targets and pathways that have been limited by safety challenges (e.g. the Delta/Notch/Jagged pathway), together with clinically and commercially validated targets for which severe toxicities have limited their full commercial potential (e.g. EGFR, CTLA-4). The company is backed by top-tier life science investors including Third Rock Ventures and the Roche Venture Fund. CytomX is located in South San Francisco, CA. For more information, please visit www.cytomx.com .

SOURCE: CytomX Therapeutics      
        Pure Communications
        Dan Budwick, 973-271-6085
       

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.